

Co-immunization with HIV-1 Vaccinogens and immunomodulators

- It is a proof of concept. This concept is specifically designed for the treatment of patients with HIV-1 subtype C infections / AIDS particularly in India.
- This technology relates to the augmentation of HIV specific immune response by co-immunization with HIV-1 vaccinogens and immunomodulators.
- **Milestones achieved:**
 - **IP Status:** An Indian patent has been granted and patent number is 218302.
 - **Validation:** The mandatory preclinical toxicity testing of vaccine constructs is under process.
 - **USP of technology:** This technology is very effective in controlling the virus replication in patients. The co-immunization of immunomodulators with vaccine constructs stimulates the HIV-1 specific immune response particularly of neutralizing antibodies and Cytotoxic T lymphocytes by several folds thereby controlling virus replication.
- Technology was developed at AIIMS, New Delhi and supported by ICMR.
- ICMR is seeking potential agencies for the up-scaling of technology.